Trial Profile
Paroxetine for the Prevention of IFN-Alpha Associated Depression in Patients With Chronic Hepatitis C
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Paroxetine (Primary)
- Indications Depression
- Focus Therapeutic Use
- 19 Nov 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT00209118).
- 05 Nov 2010 New trial record.
- 01 May 2007 Results published in Alimentary Pharmacology and Therapeutics.